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Letter: predicting azathioprine-associated pancreatitis in
IBD—phenotype or genotype? Authors’ reply
Coenen et al (2015).9 A 10-fold reduction in haematologic adverse

EDITORS,
1

We thank Teich et al for their comments and recognise there are

drug reactions was seen in the variant TPMT carriers in the inter-

differences in opinion with regards to the treatment algorithm as

vention group (2.9%) versus the control group (22.9%) with a num-

2

outlined in our study.

There are undoubtedly other risk factors

associated with the onset of azathioprine (AZA)-induced pancreatitis,

ber needed to treat of five for patients carrying a TPMT risk
allele.9

3,4

Ultimately, genotype-guided dosing algorithms for AZA have a

Our algorithm was based on new insights regarding genetic determi-

role in IBD management particularly given the number of alternative

nants of variation in drug response as a way to guide clinicians on

therapeutic agents available, as well as the continued reduction in

how to incorporate a novel genomic marker in clinical practice to

cost of genotype testing to enhance efficacy and reduce harm from

enhance the safe use of AZA.

AZA therapy.

even beyond those identified by Teich et al in their own work.

In terms of cost-effectiveness, we note that genotype-guided
dosing of AZA using TPMT genotypes has been shown to be more
cost-effective than standard practice in several studies.5-7 Thompson
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(2011).6,8 This group showed that TPMT genotyping resulted in

unchanged from those in the original article.2

lower costs compared to the standard practice of step-wise dose
escalation with monitoring of biochemical and haematological parameters.7 This confirmed work by Payne et al (2009) in an analysis of 6

LINKED CONTENT

retrospective economic evaluations of TPMT-guided AZA dosing, all

This article is linked to Wilson et al and Teich et al papers. To view

of which emphasised its cost-effectiveness compared to standard

these articles visit https://doi.org/10.1111/apt.14483 and https://

6

doi.org/10.1111/apt.14545.

practice.

While the allele frequency of the rs2647087 variant genotype is
relatively high, it is debatable whether or not AZA should be withheld from this population. The genomic data allow physicians to
enter into a more informed discussion with their patient regarding
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the risks associated with AZA, whether used as monotherapy or in
combination with a biologic, as well as discussion on other steroid-

A. Wilson1,2,3

sparing alternatives such as methotrexate. In our cohort of patients,

L. E. Jansen4

AZA-induced pancreatitis resulted in hospitalisation for all patients.

R. V. Rose5

Thus, while not severe, affected patients were of sufficient concern

J. C. Gregor2
T. Ponich2

to warrant hospitalisation.

N. Chande2

Lastly, Teich et al suggest that genomic-based dosing strategies
9

for AZA are not effective, citing Coenen et al (2015). The utility

R. Khanna2

of pre-emptive TPMT genotyping is widely accepted. Canadian,

B. Yan2

American and British Gastroenterology Society guidelines, all advo-

V. Jairath2,5

cate for pre-emptive TPMT genotyping prior to the introduction of

N. Khanna2

10-13

The evidence for TPMT-

M. Sey2

guided dosing comes from robust mechanistic studies in addition to

M. Beaton2

retrospective analyses supporting dose reduction in TPMT variant

K. McIntosh2

carriers summarised in the Clinical Pharmacogenetics Implementa-

W. A. Teft1

thiopurine-based therapies in IBD.

tion Consortium Guideline.14 Randomised control studies such as
the Coenen et al (2015) study are insufficiently powered to show

R. B. Kim1
1
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the benefit of TPMT-guided AZA dosing in general populations due
to the rarity of variant TPMT genotypes. The greatest benefit is
seen at the level of the variant carriers as was demonstrated by
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Letter: extensive intestinal metaplasia is associated with the
presence of incomplete intestinal metaplasia subtype and
could be an easier marker for high risk of gastric cancer
EDITORS,

should be included in the analysis to demonstrate that incomplete

We read with great interest the elegant study published by Pit-

GIM is truly an independent risk factor for GC. This issue is

tayanon et al1 on the risk of gastric cancer (GC) in patients with gas-

clinically important as identifying multifocal GIM is more feasible

tric intestinal metaplasia (GIM). While we agree that incomplete GIM

than GIM subtyping, especially in the era of image-enhanced

is an important risk factor for the development of GC, we think that

endoscopy.

the following issues should be considered.

Second, five out of 10 patients with incomplete GIM in this

First, extensive GIM has been recommended as a high-risk

study progressed to high-grade dysplasia or GC. Furthermore, three

marker for GC.2 This phenotype is also described as multifocal

patients progressed within 1 year of follow-up, which is much faster

2-4

Some previous studies have shown that multifocal GIM

than the progression of GIM and almost similar to the progression of

was significantly associated with the presence of the incomplete

dysplasia to GC reported in recent studies.4,6,7 Were these neo-

GIM.

3,5

However, the number of biopsy specimens

plasms detected at the same gastric locations where baseline incom-

affected with GIM from each patient in this study was not

plete GIM had been identified or from other locations? Our previous

addressed. Although the authors have included OLGIM stage in

study in Vietnamese patients with non-ulcer dyspepsia showed that

the multivariable analysis, it may not help to recognise the differ-

multifocal GIM, incomplete GIM and dysplasia tended to cluster in

ence in rates of multifocal GIM between subgroups of patients

the same group of patients, and dysplastic lesions might not be

with complete and incomplete GIM. We think that this variable

endoscopically visible.5 Is it possible that these patients already had

GIM subtype.
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